Abed Agbarya

1.4k total citations
76 papers, 896 citations indexed

About

Abed Agbarya is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Abed Agbarya has authored 76 papers receiving a total of 896 indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 39 papers in Pulmonary and Respiratory Medicine and 15 papers in Molecular Biology. Recurrent topics in Abed Agbarya's work include Lung Cancer Treatments and Mutations (28 papers), Lung Cancer Diagnosis and Treatment (12 papers) and Cancer Immunotherapy and Biomarkers (12 papers). Abed Agbarya is often cited by papers focused on Lung Cancer Treatments and Mutations (28 papers), Lung Cancer Diagnosis and Treatment (12 papers) and Cancer Immunotherapy and Biomarkers (12 papers). Abed Agbarya collaborates with scholars based in Israel, United States and Slovenia. Abed Agbarya's co-authors include Nicola J. Nasser, Barliz Waissengrin, Ido Wolf, Hagit Padova, Miguel Gorenberg, Elizabeth Dudnik, Eran Ben‐Arye, Walid Shalata, Mira Wollner and Gil Bar‐Sela and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Abed Agbarya

63 papers receiving 887 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Abed Agbarya Israel 14 456 318 207 137 99 76 896
Xiaohong Xie China 19 348 0.8× 407 1.3× 184 0.9× 90 0.7× 27 0.3× 90 999
Syed Hasan Raza Jafri United States 11 349 0.8× 188 0.6× 137 0.7× 24 0.2× 162 1.6× 29 860
Minmin Li China 19 216 0.5× 193 0.6× 236 1.1× 49 0.4× 27 0.3× 65 961
Fernando Calais da Silva Portugal 11 338 0.7× 450 1.4× 274 1.3× 45 0.3× 72 0.7× 23 1.6k
Sheng‐Hao Lin Taiwan 17 136 0.3× 363 1.1× 179 0.9× 58 0.4× 15 0.2× 50 763
Gustav Lehne Norway 19 427 0.9× 118 0.4× 326 1.6× 93 0.7× 15 0.2× 46 950
Xingyang Xue China 12 131 0.3× 100 0.3× 172 0.8× 233 1.7× 51 0.5× 25 568
Ya‐Fang Huang Taiwan 20 307 0.7× 120 0.4× 532 2.6× 31 0.2× 23 0.2× 31 1.2k
Ikuya Miki Japan 19 309 0.7× 323 1.0× 196 0.9× 81 0.6× 13 0.1× 65 1.1k
Yiqing Xu United States 15 393 0.9× 176 0.6× 393 1.9× 29 0.2× 11 0.1× 48 891

Countries citing papers authored by Abed Agbarya

Since Specialization
Citations

This map shows the geographic impact of Abed Agbarya's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Abed Agbarya with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Abed Agbarya more than expected).

Fields of papers citing papers by Abed Agbarya

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Abed Agbarya. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Abed Agbarya. The network helps show where Abed Agbarya may publish in the future.

Co-authorship network of co-authors of Abed Agbarya

This figure shows the co-authorship network connecting the top 25 collaborators of Abed Agbarya. A scholar is included among the top collaborators of Abed Agbarya based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Abed Agbarya. Abed Agbarya is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yakobson, Alexander, et al.. (2025). Exploring the Impact of TP53 Mutation and Wild-Type Status on the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences. 26(14). 6939–6939. 1 indexed citations
2.
Agbarya, Abed, et al.. (2025). Real-World Data on Osimertinib-Associated Cardiac Toxicity. Journal of Clinical Medicine. 14(5). 1754–1754. 2 indexed citations
3.
Shalata, Walid, et al.. (2025). Correlation Between Body Mass Index and Immunotherapy Response in Advanced NSCLC. Cancers. 17(7). 1149–1149.
4.
Agbarya, Abed, et al.. (2024). Clinical Versus Pathological Staging in Patients with Resected Ground Glass Pulmonary Lesions. Diagnostics. 14(24). 2874–2874.
5.
Musa, Sanaa, et al.. (2024). Overcoming Chemoresistance in Cancer: The Promise of Crizotinib. Cancers. 16(13). 2479–2479. 12 indexed citations
6.
Shalata, Walid, Waleed Kian, Rafał Dziadziuszko, et al.. (2024). Non-Small-Cell Lung Cancer Patients Harboring ROS1 Rearrangement: Real World Testing Practices, Characteristics and Treatment Patterns (ROS1REAL Study). Current Oncology. 31(8). 4369–4381. 1 indexed citations
7.
Sheikh‐Ahmad, Mohammad, Jacob Bejar, Ibrahim Matter, et al.. (2023). Factors Predicting Type I Gastric Neuroendocrine Neoplasia Recurrence: A Single-Center Study. Biomedicines. 11(3). 828–828. 5 indexed citations
8.
Shalata, Walid, et al.. (2023). Unexpected and Rare Sites of Metastasis in Oncologic Patients. Journal of Clinical Medicine. 12(20). 6447–6447.
9.
Levy, Ilana, et al.. (2023). Acupuncture in the Treatment of Panitumumab Skin Toxicity: A Case Report. Complementary Medicine Research. 30(1). 78–83.
10.
11.
Waissengrin, Barliz, et al.. (2021). Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors (vol 22, pg 581, 2021). The Lancet Oncology. 22(6). 2 indexed citations
12.
Waissengrin, Barliz, et al.. (2021). Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors. The Lancet Oncology. 22(5). 581–583. 117 indexed citations
13.
Gorenberg, Miguel, et al.. (2021). Novel nanotech antioxidant cocktail prevents medical diagnostic procedures ionizing radiation effects. Scientific Reports. 11(1). 5315–5315. 2 indexed citations
14.
15.
Rennert, Gad, Maya Gottfried, Hedy S. Rennert, et al.. (2020). Long term follow-up of EGFR mutated NSCLC cases. Translational Oncology. 14(1). 100934–100934. 8 indexed citations
16.
Agbarya, Abed, Alfredo Addeo, Kristof Cuppens, et al.. (2020). 1683P SARS-CoV-2 infection and lung cancer management in Europe. Annals of Oncology. 31. S996–S997. 2 indexed citations
17.
Dudnik, Elizabeth, Mor Moskovitz, Abed Agbarya, et al.. (2019). OA11.06 Alternative Nivolumab (N) Duration and Scheduling in Advanced Non-Small Cell Lung Cancer (aNSCLC): Real-Life Data. Journal of Thoracic Oncology. 14(10). S235–S236. 6 indexed citations
18.
Issa, Nidal, et al.. (2015). Transanal Endoscopic Microsurgery After Neoadjuvant Chemoradiotherapy for Rectal Cancer. Journal of Laparoendoscopic & Advanced Surgical Techniques. 25(8). 617–624. 5 indexed citations
19.
Ben‐Arye, Eran, Elad Schiff, Michael Silbermann, Abed Agbarya, & Gil Bar‐Sela. (2014). Perceptions of Complementary Medicine Integration in Supportive Cancer Care of Arabs and Jews in Israel: A Cross-Cultural Study. Journal of Pain and Symptom Management. 49(5). 871–877. 15 indexed citations
20.
Agbarya, Abed, et al.. (2014). Hormone dependent metastatic salivary gland carcinoma: a case report. SpringerPlus. 3(1). 363–363. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xiaohong Xie Breakdown of academic impact, for papers by Syed Hasan Raza Jafri Breakdown of academic impact, for papers by Minmin Li Breakdown of academic impact, for papers by Fernando Calais da Silva Breakdown of academic impact, for papers by Sheng‐Hao Lin Breakdown of academic impact, for papers by Gustav Lehne Breakdown of academic impact, for papers by Xingyang Xue Breakdown of academic impact, for papers by Ya‐Fang Huang Breakdown of academic impact, for papers by Ikuya Miki Breakdown of academic impact, for papers by Yiqing Xu
Rankless by CCL
2026